Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07425821 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT07425821 is a Phase 1 study that is actively recruiting participants, run by International AIDS Vaccine Initiative. The registered enrollment target is 112 participants.
The verdict
NCT07425821, a Phase 1 study, is actively recruiting participants, sponsored by International AIDS Vaccine Initiative.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Interventions
- OTHER Placebo
- BIOLOGICAL rVSV∆G-MARV-GP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07425821
The ClinicalTrials.gov registry entry for NCT07425821 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07425821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07425821 about?
NCT07425821 is a clinical study titled "A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health". A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
What is the current status of trial NCT07425821?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2026-03-27. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07425821?
The interventions under investigation include: Placebo (OTHER), rVSV∆G-MARV-GP (BIOLOGICAL).
Who is sponsoring clinical trial NCT07425821?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.